Results 171 to 180 of about 82,006 (284)
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada +3 more
wiley +1 more source
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper +5 more
wiley +1 more source
Carbamazepine-induced acute generalized exanthematous pustulosis triggering diabetic ketoacidosis in a patient with type II diabetes mellitus: a case report. [PDF]
Bastola B, Bohora LR.
europepmc +1 more source
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli +8 more
wiley +1 more source
Dissolved Organic Matter and Pretreatment Effects on PFAS Removal by Granular Activated Carbon
ABSTRACT Granular activated carbon (GAC) adsorption is commonly used to remove per‐ and polyfluoroalkyl substances (PFAS) from water. In this study, we evaluated the impact of dissolved organic matter (DOM) concentration and pretreatment on GAC use rates for PFAS removal.
Tiffany Tang +2 more
wiley +1 more source
Epilepsy in Chinese Children With Mowat–Wilson Syndrome: Two Case Reports and Literature Review
Journal of Paediatrics and Child Health, EarlyView.
Xuelin Huang +6 more
wiley +1 more source
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou +2 more
wiley +1 more source
Pain That Challenges Survival: A Novel <i>SCN9A</i> Variant (p.Leu1623Gln) Causing Carbamazepine-Refractory Paroxysmal Extreme Pain Disorder in a Chinese Family - Case Report. [PDF]
Yip MK, Liu CJ, Poon WT.
europepmc +1 more source
ABSTRACT This was the case of a 62‐year‐old patient treated with cabozantinib and nivolumab for metastatic clear cell renal cell carcinoma, in whom a clinically significant pharmacokinetic interaction with carbamazepine was observed. Carbamazepine, a potent inducer of CYP3A4, caused a major decrease in systemic exposure to cabozantinib, as confirmed by
Pierre Nizet +4 more
wiley +1 more source

